Bristol-Myers Squibb Company and Pfizer Inc. recently announced findings from a real-world data analysis of the U.S. Medicare database that compares risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants versus warfarin. Read More »

In honor of Multiple Sclerosis Awareness Month, Acorda Therapeutics recently launched a new Alexa skill called MS Awareness Facts that will help Amazon Alexa users learn more about the chronic disease and its symptoms.   Read More »

Pfizer Inc.'s combination antibiotic Zavicefta is now available in the United Kingdom and Germany for the treatment of Gram-negative bacterial infections requiring hospitalization. Read More »

Regeneron and Sanofi are set to present new data from the Phase 3 Praluent (alirocumab) injection clinical trial program at this weekend’s American College of Cardiology Scientific Sessions (ACC 17) in Washington, D.C. Read More »

The U.S. Food and Drug Administration has accepted a supplemental New Drug Application for Auryxia tablets from Keryx Biopharmaceuticals Inc., a company specializing in innovative medicines to fight renal disease. Read More »

Chinese authorities recently approved Pfizer China’s oral Janus kinase inhibitor XELJANZ, with active ingredient tofacitinib citrate, indicated for treating adults with moderate to severely active rheumatoid arthritis. Read More »

Regeneron Pharmaceutical Inc. and Sanofi recently presented the results of their one-year Phase 3 CHRONOS study, showing that investigational drug DUPIXENT combined with topical corticosteroids achieved better results in treating uncontrolled moderate-to-severe atopic dermatitis than TCS alone. Read More »

The U.S. Food and Drug Administration recently issued Investigational New Drug clearance for Servier’s UCART19, allowing the company to proceed with clinical development of the allogeneic, gene-edited cellular therapy. Read More »

The U.S. Patent and Trademark Office Patent Trials and Appeal Board recently upheld four patents held by Acorda Therapeutics Inc. related to its AMPYRA (dalfampridine) Extended Release Tablets in 10 mg dosages. Read More »

Pfizer Inc. is renewing its partnership with the Union for International Cancer Control through a grant of $530,000 for the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge. Read More »

Bristol-Myers Squibb Co. and Pfizer Inc. will present eight of their abstracts at the American College of Cardiology's 66th Annual Scientific Session in Washington, D.C. March 17-19. Read More »

Merck, which is known as MSD outside the United States and Canada, and Pfizer Inc. recently announced the acceptance for review of three New Drug Applications by the U.S. Food and Drug Administration. Read More »

Immune Pharmaceuticals Inc. will broaden enrollment eligibility criteria for its 10-patient open label study of Bertilimumab in the treatment of Bullous Pemphigoid (BP) after data was compiled from three patients who completed treatment. Read More »

Acorda Therapeutics' CVT-301, a drug used in treating people with Parkinson’s disease, showed significant improvement in motor functions during a Phase 3 clinical trial. Read More »

Pharmaceutical companies, trial lawyers and tort reform advocates are closely following a case that the U.S. Supreme Court has taken up that addresses the issue of plaintiffs joining suits in other states. Read More »

Pfizer Inc. has partnered with relationship expert Logan Levkoff to host a Q&A session on relationship and intimacy advice for people dealing with chronic diseases.  Read More »

Biotechnology company Acorda Therapeutics Inc., which is known for its work in neurological disorders, will present at two investor conferences this month.  Read More »

Relmada Therapeutics, a biopharmaceutical company that specializes in developing treatments for central nervous system diseases, received approval from the U.S. Food and Drug Administration to advance a new therapy to clinical trials. Read More »

President Donald Trump said before winning the election that the Affordable Care Act was one of the top items to be eliminated when he took office. Read More »

Robert Kennedy Jr. has announced he will chair President Donald Trump's new commission on vaccine safety. Read More »